Please assess the completion status of the following clinical trial:

Trial Title: Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective~* Eastern Cooperative Oncology Group (ECOG) performance status \</= 2~* Life expectancy greater than 3 months~* Adequate organ and marrow function~* Written informed consent~* Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study~* In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST~Exclusion Criteria:~* Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184~* Administration of an investigational drug within 30 days of the first dose of XL184~* Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment~* Known brain metastases~* Uncontrolled intercurrent illness~* Pregnancy or breastfeeding~* Known HIV positive~* Known allergy or hypersensitivity to any of the components of the XL184 formulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).